Editorial on the relationship between suPAR and CKD, published in NEJM
Wed Oct 21 2020
The New England Journal of Medicine recently published an article titled “A suPAR Biomarker for Chronic Kidney Disease,” highlighting a significant advancement in the detection and management of Chronic Kidney Disease (CKD). CKD is a widespread global health issue that often results in death, especially in regions lacking access to renal-replacement therapies. Early detection of CKD is essential for effective treatment, yet current diagnostic methods typically identify the disease only after substantial kidney damage has occurred. Consequently, there is an urgent need for new biomarkers that can accurately assess CKD risk while kidney function is still intact. This would enhance the likelihood that treatments can slow or even halt the disease’s progression.
The article emphasizes the potential of suPAR (soluble urokinase-type plasminogen activator receptor) as a biomarker for CKD. Unlike traditional methods that detect decreased renal function only after significant damage, suPAR levels can indicate the risk of CKD much earlier in the disease process. This early detection is crucial for initiating interventions that could prevent further kidney damage and improve patient outcomes.
Research indicates that high suPAR levels are associated with an increased risk of developing CKD. By incorporating suPAR measurement into routine clinical practice, healthcare providers could identify at-risk patients sooner and implement preventive measures. This proactive approach could significantly reduce the burden of CKD on patients and healthcare systems worldwide.
Furthermore, studies that demonstrate the effectiveness of interventions based on suPAR levels could solidify the connection between suPAR and CKD. These studies would provide robust evidence supporting suPAR as a reliable biomarker for early CKD detection and risk assessment. If such interventions prove successful, they could transform the current approach to CKD management, shifting the focus from late-stage treatment to early prevention and care.
